stockportfolio.pro
Stocks / BMY vs SYK
BMY vs SYK
Bristol-Myers Squibb Company and Stryker Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Bristol-Myers Squibb Company (BMY) | Stryker Corporation (SYK) | |
|---|---|---|
| Market cap | $115.3B | $120.4B |
| Revenue (latest FY) | $48.19B | $25.12B |
| Net income (latest FY) | $7.05B | $3.25B |
| Revenue growth (5y CAGR) | 2.5% | 11.8% |
| Net margin | 14.6% | 12.9% |
| Return on equity | 38.2% | 14.5% |
| P/E ratio | 15.8 | 36.3 |
| Dividend yield | 4.5% | 1.2% |
| Profitable years (of last 10) | 8 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BMY — free Open SYK — freeFrequently asked questions
Which is bigger, BMY or SYK?
Stryker Corporation is larger by market capitalization — $120.4B versus $115.3B.
Which grows faster, BMY or SYK?
Over the last five fiscal years, Stryker Corporation grew revenue faster — 11.8%/yr versus 2.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.